Wegovy label revision consolidates pregnancy, lactation and pediatric guidance

The prescribing information for Wegovy (semaglutide), revised in June 2026, now lists two contraindications, eleven Warnings and Precautions, and consolidated guidance on pregnancy, breastfeeding, and use in adolescents ^[1]. The update does not add a new medical warning about pregnancy risk itself, but it groups existing instructions in one section so prescribers and patients can find them together ^[1].

The two contraindications remain a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and known hypersensitivity to semaglutide or its inactive ingredients ^[1]. The eleven Warnings and Precautions cover thyroid C-cell tumor risk, acute pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity reactions, diabetic retinopathy complications, heart rate increase, pulmonary aspiration during general anesthesia or deep sedation, and a new instruction not to share the Wegovy FlexTouch pen between patients even with a new needle ^[1].

On reproduction, the label says Wegovy "may cause fetal harm" and instructs patients receiving the drug for cardiovascular risk reduction, weight reduction, or MASH to stop it at least two months before a planned pregnancy, citing semaglutide's long half-life ^[1]. For breastfeeding, the label states that it "is not recommended during treatment with WEGOVY tablets," a statement specific to the oral form of the drug ^[1].

On pediatric use, the injectable form is indicated for weight reduction in patients 12 years and older with obesity, combined with a reduced-calorie diet and increased physical activity, while the tablet form's approved uses are limited to reducing major cardiovascular events in adults with established cardiovascular disease and obesity or overweight ^[1]. The label also shows a history of recent revisions: dosage and administration language changed three times between August 2025 and March 2026, a warning about acute kidney injury from volume depletion was added in August 2025, a warning about severe gastrointestinal adverse reactions was added in October 2025, a prior warning about suicidal behavior and ideation was removed in January 2026, and the new pen-sharing warning was added in June 2026 ^[1].

Why it matters for patients

For people who are pregnant, trying to conceive, or breastfeeding, this update means the label now spells out timing guidance in a single, easier-to-find place rather than scattering it across sections ^[1]. Patients planning a pregnancy can see the specific two-month window tied to how long semaglutide stays in the body ^[1]. Those who are breastfeeding can see that the tablet form specifically is not recommended during treatment, though the sources do not specify separate breastfeeding guidance for the injectable form ^[1].

For adolescents and their families, the label confirms that Wegovy injection remains approved for weight reduction starting at age 12, while the newer tablet form's approval for cardiovascular risk reduction applies only to adults ^[1]. The pulmonary aspiration warning, tied to anesthesia or deep sedation, is relevant for anyone with a planned surgery or procedure, since the label instructs patients to tell their healthcare providers about their Wegovy use beforehand ^[1].

The removal of the suicidal behavior and ideation warning in January 2026 is noted in the label's revision history, but the sources provided do not explain the reasoning behind that removal or what evidence prompted it ^[1].

What happens next

The label reflects revisions current as of June 2026 ^[1]. The sources do not indicate any additional label changes planned beyond this date, so what happens next for future revisions is not yet known from the material provided.